Combo checkpoint inhibitors: riding for a fall?

Jumping directly from a Phase 1 to a Phase 3 clinical trial for a NSCLC treatment combo without “further investigation” may lead to “negative consequences”, a US oncologist warns.

Commenting on a Phase 1b safety study of two checkpoint inhibitors for non-small cell lung cancer in the Lancet Oncology, Dr Edward Garon says the situation appears different from that in melanoma, where the combination